Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT03971669

PHASE4

Blood Donor CVD 5000

Sponsor: University of Maryland, Baltimore

View on ClinicalTrials.gov

Summary

This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries. Volunteers will also be asked to provide blood, saliva, and stool specimens over a follow-up time period of up to eight years. The specimens obtained in this clinical research study will be used to further the investigator's understanding of the protective immunological mechanisms that can be elicited systemically and may be applicable to other enteric pathogens.

Official title: Collection of Blood Samples for In-Vitro Studies From Healthy Adult Blood Donors Who Have Received Oral Typhoid Vaccine (TY21A)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2004-01-16

Completion Date

2030-06-30

Last Updated

2026-03-27

Healthy Volunteers

Yes

Conditions

Risk Reduction

Interventions

DRUG

Vivotif Typhoid Oral Vaccine

The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).

Inclusion Criteria: * Age 18 years and older * Good general health as determined by a screening evaluation within 28 days before blood donation * Informed, written consent Exclusion Criteria: * History of any of the following medical illnesses: * Diabetes * Cancer in past 5 years (except for basal cell carcinoma of the skin and cervical carcinoma in situ) * Heart disease (Hospitalization for a heart attack, coronary artery bypass graft, arrhythmia, or syncope, within past 5 years. Current symptoms of heart disease - dyspnea, angina, orthopnea) * Recurrent infections (more than 3 hospitalizations for invasive bacterial infections such as pneumonia or meningitis) * Current drug or alcohol abuse * Active ulcer disease or ongoing intestinal condition * Treatment for anemia in last 6 months * Currently being treated with anti-malarial drugs * Any of the following laboratory abnormalities detected during medical screening: * WBC \<0.81 x LLN or \> 1.09 x ULN * Hemoglobin \<0.91 x LLN or \>1.18 x ULN (women) or \<0.92 x LLN or \>1.18 x ULN (men) * Platelet count \<0.8 x LLN or \> 1.2 x ULN * (For leukopheresis or blood unit donations, the following lab values are exclusionary: * WBC \<3.5 or \>11 x 103/mm3; * Hemoglobin \<12.5 or \>18 g/dl * Platelet count \<150 or \>500 x 103/mm3) * SGOT or SGPT \>1.5 times normal * Positive serology for hepatitis C or HIV antibody or hepatitis B surface antigen * Positive serology for hepatitis B core antibody * Poor peripheral venous access for blood donation * Positive RPR * Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or interfere with the scientific integrity of study. * Positive urine pregnancy test (HCG) on day of vaccination. Prior to each blood donation -females with menstrual history consistent with pregnancy. Pregnant women will not be enrolled, because immunological changes that occur during pregnancy may interfere with laboratory assays.

Locations (1)

University of Maryland, Baltimore, Center for Vaccine Development and Global Health

Baltimore, Maryland, United States